Feb 7, 2023
Lixte Biotechnology Holdings, Inc. Reports That Its Lead Clinical Compound, Lb-100, Can Kill Cancer Cells Through Hyper-Stimulation of Cell Proliferation Signals in Pre-Clinical Models
Posted by Quinn Sena in category: biotech/medical
—THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE”
—THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN KILLING CANCER CELLS IN SEVERAL PRE-CLINICAL CANCER MODELS
—RESISTANCE TO THIS THERAPY CAN RESULT IN THE LOSS OF THE ONCOGENIC PROPERTIES OF CANCER CELLS